Recent developments include the Q3 2026 earnings call, the acquisition of 85% of NeuroNOS by XTL Biopharmaceuticals, appointment of a new CFO, and reports of significant sales growth.

• Beyond Air held its Q3 2026 earnings call providing updates on commercial and clinical progress [N1].
• XTL Biopharmaceuticals acquired 85% of Beyond Air’s subsidiary NeuroNOS, focusing on autism therapeutics with Nobel Prize-winning scientific leadership [N2].
• Dan Moorhead was named CFO of Beyond Air in December 2025 [N3].
• D. Boral Capital maintained a buy recommendation on Beyond Air in November 2025 [N4].
• Beyond Air reported a 158 percent increase in sales as of August 2025 [N5].
• The company held its Q1 2026 earnings call in August 2025, discussing financial results and business updates [N6].
• Beyond Air reported a Q1 loss and lagging revenue in August 2025 [N7].

Beyond Air's LungFit® platform offers a novel approach to nitric oxide delivery with regulatory approvals in key markets and a growing commercial footprint. The development of the second-generation LungFit® PH II device aims to expand addressable markets by enabling transport-ready use. Clinical data supporting LungFit® PRO and LungFit® GO for viral lung infections and NTM lung disease indicate potential for broader therapeutic applications. Strategic partnerships and majority ownership in subsidiaries targeting oncology and neurological disorders diversify the company's portfolio. The recent acquisition of NeuroNOS by XTL Biopharmaceuticals may provide capital and focus for autism therapeutics development. Strong liquidity ratios as of March 2026 support ongoing operations and development efforts.

Beyond Air operates in a highly regulated and competitive medical device and biopharmaceutical market with significant clinical and regulatory risks. The company reported a substantial net loss for fiscal 2026, indicating ongoing operating expenses exceeding revenues. Some clinical trials, such as the LungFit® PRO study in the U.S., have been terminated, reflecting challenges in clinical development. The proposed acquisition of NeuroNOS by XTL Biopharmaceuticals is subject to customary closing conditions and may not be consummated, potentially impacting strategic direction. Market adoption of LungFit® devices depends on reimbursement, hospital acceptance, and competition from established NO delivery systems. The company’s financial disclosures do not include revenue figures, limiting visibility into commercial performance.

Beyond Air's competitive advantages stem from its patented LungFit® platform technology that generates nitric oxide from ambient air, eliminating the need for high-pressure cylinders and cumbersome purging procedures common in traditional NO delivery systems. The LungFit® PH device is the first FDA-approved and CE marked system using this technology, providing a unique product in the pulmonary hypertension treatment market. The company's regulatory approvals across multiple countries and established distribution agreements support its commercial reach. Additionally, its diversified pipeline targeting viral lung infections, nontuberculous mycobacteria infections, and neurological conditions through majority-owned subsidiaries provides multiple avenues for innovation and market expansion. The proprietary technology and regulatory clearances create barriers to entry for competitors in the inhaled nitric oxide treatment space.

• Regulatory and Clinical Development Risks: The company’s products and pipeline candidates require ongoing regulatory approvals and successful clinical trials. Failure to obtain or maintain approvals could adversely affect operations.
• Financial Performance and Liquidity Risks: Beyond Air reported a net loss of $33.2 million for fiscal 2026 and depends on sufficient liquidity and capital to fund operations and development.
• Transaction Risk Related to NeuroNOS Acquisition: The proposed acquisition of NeuroNOS by XTL Biopharmaceuticals is subject to conditions and may not be completed, which could materially impact Beyond Air’s business and strategic plans.
• Market Adoption and Competitive Risks: Adoption of LungFit® devices depends on hospital acceptance, reimbursement, and competition from existing NO delivery systems, which may limit market penetration.

• Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems called the LungFit® platform that generates NO from ambient air [S1].
• The company's first device, LungFit® PH, received FDA premarket approval (PMA) in June 2022 for treatment of persistent pulmonary hypertension of the newborn (PPHN) in term and near-term neonates [S1].
• LungFit® PH received European CE mark approval in November 2024 for treatment of infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension in pediatric and adult patients [S1].
• LungFit® PH can generate NO up to 400 ppm and deliver it continuously or for fixed times at various flow rates, with dose titration or constant dose capability [S1].
• The company markets LungFit® PH in the U.S. and has regulatory approvals in over 27 countries plus distribution agreements covering more than 40 countries [S1].
• Beyond Air is developing second generation LungFit® PH II, which is smaller, lighter, and transport-ready, with a PMA supplement submitted to FDA in June 2025 [S1].
• The estimated total addressable market for inhaled NO in the U.S. is approximately $350 million and worldwide $700 million or greater [S1].
• Beyond Air is developing LungFit® PRO for treatment of viral lung infections including COVID-19 and bronchiolitis, with clinical trials conducted and some terminated [S1].
• The company is developing LungFit® GO for treatment of nontuberculous mycobacteria (NTM) lung infections, with clinical trials funded partly by a grant from the Cystic Fibrosis Foundation [S1].
• Beyond Air has two additional programs outside the LungFit® platform: Beyond Cancer, Ltd. (80% owned) targeting solid tumors with ultra-high concentration NO delivery, and NeuroNOS Limited (84.75% owned) developing nNOS inhibitors for neurological conditions including autism spectrum disorder (ASD) [S1].
• In January 2026, XTL Biopharmaceuticals acquired 85% of Beyond Air's subsidiary NeuroNOS, focusing on autism therapeutics [N2].
• Dan Moorhead was named CFO in December 2025 [N3].
• The company reported a net loss of $33.2 million and basic and diluted EPS of -$4.01 for fiscal year ended March 31, 2026 [S1].
• As of March 31, 2026, Beyond Air had $6.74 million in cash and equivalents, $4.9 million in short-term investments, current assets of $24.77 million, current liabilities of $6.51 million, a current ratio of 3.8, and a cash ratio of 1.79 [S1].
• The company initiated commercial launch phases for LungFit® PH starting July 2022 and expanded commercial presence in spring 2023 in the U.S. [S1].
• Recent news includes Q3 2026 earnings call transcript and corporate developments such as the NeuroNOS acquisition and CFO appointment [N1,N2,N3].